Search
Isocarboxazid
go.drugbank.com/drugs/DB01247Approved[T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959. … [A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Monoamine Oxidase Inhibitors, Non-SelectivePhenoxypropazine
go.drugbank.com/drugs/DB09251ApprovedWithdrawnIt was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential. … Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the _hydrazine_ chemical class.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeIndocyanine green acid form
go.drugbank.com/drugs/DB09374ApprovedInvestigationalEach vial of Indocyanine Green for Injection USP contains 25 mg of Indocyanine Green as a sterile lyophilized powder with no more than 5% sodium iodide. … Indocyanine Green for Injection USP has a pH of approximately 6.5 when reconstituted.
Categories: Compounds used in a research, industrial, or household settingHydroxyzine
go.drugbank.com/drugs/DB00557ApprovedInvestigational[L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. … [A189753] Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety.[L9677]
Products: Nu-hydroxyzineClioquinol
go.drugbank.com/drugs/DB04815ApprovedVet approvedWithdrawnClioquinol was withdrawn in 1983 due to neurotoxicity.
Mixtures: CORTINOL D, Phenoris OntSynonyms: 5-chloro-7-iodoquinolin-8-olDiroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigational[A176474] It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. … Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS.
Florilglutamic acid F-18
go.drugbank.com/drugs/DB15041InvestigationalFlorilglutamic acid F-18 is under investigation in clinical trial NCT02370563 (PET Imaging of Intracranial Cancers With 18F-FSPG).
Tolfenamic acid
go.drugbank.com/drugs/DB09216Approved[L1292] In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291] … [A31824] It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSPegvaliase
go.drugbank.com/drugs/DB12839ApprovedInvestigational[L42725] It is advantageous over currently available management therapies for PKU, such as [DB00360], that are ineffective to many patients due to long-term adherence issues or inadequate Phe-lowering … The primary goal of lifelong treatment of PKU, as recommended by the American College of Medical Genetics and Genomics (ACMG) guidelines, is to maintain blood Phe concentration in the range of 120 µmol
Melphalan
go.drugbank.com/drugs/DB01042ApprovedInvestigational[L40928] It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. … Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent.
Synonyms: 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine, p-Di-(2-chloroethyl)amino-L-phenylalanine